Biotech entity

Korlym

Product

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Corcept Therapeutics Incorporated, the most common co-covered peer. Korlym appears in 1 tracked Biotech story from February 24, 2026. The tracked stories average 10 original sources each.

Last mentioned: Feb 24, 2026

Entity pulse

Recent coverage · Korlym

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Korlym

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Corcept Therapeutics Incorporated, the most common co-covered peer. Korlym appears in 1 tracked Biotech story from February 24, 2026. The tracked stories average 10 original sources each.

Stories tracked
1
Sources per story
10

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Korlym. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lawsuit Announced

    Rosen Law Firm announces the filing of the securities fraud class action.

  2. Appellate Loss

    Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.

  3. Class Period Ends

    Conclusion of the period following corrective disclosures or market events.

  4. Class Period Begins

    Start of the period during which alleged misleading statements were made.

Stories mentioning Korlym 1

Pharma Neutral

Corcept Therapeutics Faces Securities Fraud Lawsuit Amid Korlym Patent Battle

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.

10 sources

Korlym is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.